Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for hidden clues to inflammatory bowel disease

NCT ID NCT06956703

Recruiting now Knowledge-focused Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This observational study compares inflammatory markers in the blood and tissue of people with active Crohn's disease or ulcerative colitis versus healthy volunteers. Researchers aim to identify differences in the IL-23/Th17 inflammatory pathway and other immune signals. The study involves 240 participants and includes analysis of stool samples and genetic material. Findings may help uncover new targets for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If differences in inflammatory markers are found, this could point toward new targets for treating IBD.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to any direct benefit for participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease Digestive System Diseases digestive system disorder inflammatory bowel disease intestinal disorder ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE GASTRO-INTESTINAL DISORDER INFLAMMATORY BOWEL DISEASES ULCERATIVE COLITIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • University of Nottingham

    RECRUITING

    Nottingham, Nottinghamshire, NG7 2UH, United Kingdom

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.